少突胶质细胞瘤患者的存活率与循环 B 细胞和年龄有关。

IF 3.7 Q1 CLINICAL NEUROLOGY
Neuro-oncology advances Pub Date : 2024-08-19 eCollection Date: 2024-01-01 DOI:10.1093/noajnl/vdae143
Jennie W Taylor, Gayathri Warrier, Helen M Hansen, Lucie McCoy, Terri Rice, Geno Guerra, Stephen S Francis, Jennifer L Clarke, Paige M Bracci, Sara Hadad, Karl T Kelsey, Margaret Wrensch, Annette M Molinaro, John K Wiencke
{"title":"少突胶质细胞瘤患者的存活率与循环 B 细胞和年龄有关。","authors":"Jennie W Taylor, Gayathri Warrier, Helen M Hansen, Lucie McCoy, Terri Rice, Geno Guerra, Stephen S Francis, Jennifer L Clarke, Paige M Bracci, Sara Hadad, Karl T Kelsey, Margaret Wrensch, Annette M Molinaro, John K Wiencke","doi":"10.1093/noajnl/vdae143","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Variations in survival among patients with oligodendroglioma are unexplained by known prognostic factors. To assess the impact of peripheral immune profiles on prognosis, we applied immunomethylomics analyses-DNA methylation of archived whole blood samples, to characterize immune cells.</p><p><strong>Methods: </strong>We compared the proportions of immune cells from patients with oligodendroglioma to other glioma subtypes and controls. We used recursive partitioning analysis (RPA) within the oligodendrogliomas to correlate with survival.</p><p><strong>Results: </strong>Patients with oligodendrogliomas (141) were median age at diagnosis of 44 years; 57% male; 75% White; 60% prior chemotherapy; and 25% on dexamethasone at sample collection. Patients with oligodendrogliomas had immune profiles more similar to controls than other glioma subtypes, though with notably lower B-cells. RPA of patients with oligodendrogliomas delineated 2 survival groups based on an interaction between age and B-naïve cells. Patients with longer survival (median 24.2 years) were ≤42 years of age with higher B-naïve cells versus worse survival (median 16.9 years) who were ≤42 years of age with lower B-naïve cells or >42 years of age (<i>P</i> = .00032). Patients with worse survival also had lower CD4- and CD8-naïve T-cells. Similar immune profiles were observed in an independent cohort of oligodendroglioma patients prior to surgery.</p><p><strong>Conclusions: </strong>Peripheral blood immune profiles in oligodendroglioma suggested that younger patients with lower B-naïve cells experienced shorter survival. Though our findings lack of validation cohort and use a heterogenous patient population, they suggest peripheral blood immune profiles may be prognostic for patients with glioma and warrant further investigation.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379917/pdf/","citationCount":"0","resultStr":"{\"title\":\"Oligodendroglioma patient survival is associated with circulating B-cells and age.\",\"authors\":\"Jennie W Taylor, Gayathri Warrier, Helen M Hansen, Lucie McCoy, Terri Rice, Geno Guerra, Stephen S Francis, Jennifer L Clarke, Paige M Bracci, Sara Hadad, Karl T Kelsey, Margaret Wrensch, Annette M Molinaro, John K Wiencke\",\"doi\":\"10.1093/noajnl/vdae143\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Variations in survival among patients with oligodendroglioma are unexplained by known prognostic factors. To assess the impact of peripheral immune profiles on prognosis, we applied immunomethylomics analyses-DNA methylation of archived whole blood samples, to characterize immune cells.</p><p><strong>Methods: </strong>We compared the proportions of immune cells from patients with oligodendroglioma to other glioma subtypes and controls. We used recursive partitioning analysis (RPA) within the oligodendrogliomas to correlate with survival.</p><p><strong>Results: </strong>Patients with oligodendrogliomas (141) were median age at diagnosis of 44 years; 57% male; 75% White; 60% prior chemotherapy; and 25% on dexamethasone at sample collection. Patients with oligodendrogliomas had immune profiles more similar to controls than other glioma subtypes, though with notably lower B-cells. RPA of patients with oligodendrogliomas delineated 2 survival groups based on an interaction between age and B-naïve cells. Patients with longer survival (median 24.2 years) were ≤42 years of age with higher B-naïve cells versus worse survival (median 16.9 years) who were ≤42 years of age with lower B-naïve cells or >42 years of age (<i>P</i> = .00032). Patients with worse survival also had lower CD4- and CD8-naïve T-cells. Similar immune profiles were observed in an independent cohort of oligodendroglioma patients prior to surgery.</p><p><strong>Conclusions: </strong>Peripheral blood immune profiles in oligodendroglioma suggested that younger patients with lower B-naïve cells experienced shorter survival. Though our findings lack of validation cohort and use a heterogenous patient population, they suggest peripheral blood immune profiles may be prognostic for patients with glioma and warrant further investigation.</p>\",\"PeriodicalId\":94157,\"journal\":{\"name\":\"Neuro-oncology advances\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379917/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/noajnl/vdae143\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/noajnl/vdae143","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:已知的预后因素无法解释少突胶质细胞瘤患者生存率的变化。为了评估外周免疫特征对预后的影响,我们对存档全血样本进行了免疫组学分析--DNA甲基化,以确定免疫细胞的特征:我们比较了少突胶质细胞瘤患者与其他胶质瘤亚型和对照组的免疫细胞比例。我们在少突胶质细胞瘤中使用递归分区分析法(RPA)将其与存活率联系起来:少突胶质细胞瘤患者(141例)诊断时的中位年龄为44岁;57%为男性;75%为白人;60%曾接受化疗;25%在采集样本时服用地塞米松。与其他胶质瘤亚型相比,少突胶质细胞瘤患者的免疫特征与对照组更为相似,但B细胞明显较少。少突胶质细胞瘤患者的RPA根据年龄和B-幼稚细胞之间的相互作用划分出两个生存组。生存期较长(中位 24.2 年)的患者年龄小于 42 岁,B-幼稚细胞较高,而生存期较差(中位 16.9 年)的患者年龄小于 42 岁,B-幼稚细胞较低或大于 42 岁(P = 0.00032)。存活率较低的患者的 CD4- 和 CD8- 天性 T 细胞也较低。在一个独立的少突胶质细胞瘤患者队列中也观察到了类似的术前免疫特征:少突胶质细胞瘤患者的外周血免疫图谱显示,B-幼稚细胞较少的年轻患者生存期较短。虽然我们的研究结果缺乏验证队列,而且使用的是异质性患者人群,但它们表明外周血免疫图谱可能是胶质瘤患者的预后指标,值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Oligodendroglioma patient survival is associated with circulating B-cells and age.

Background: Variations in survival among patients with oligodendroglioma are unexplained by known prognostic factors. To assess the impact of peripheral immune profiles on prognosis, we applied immunomethylomics analyses-DNA methylation of archived whole blood samples, to characterize immune cells.

Methods: We compared the proportions of immune cells from patients with oligodendroglioma to other glioma subtypes and controls. We used recursive partitioning analysis (RPA) within the oligodendrogliomas to correlate with survival.

Results: Patients with oligodendrogliomas (141) were median age at diagnosis of 44 years; 57% male; 75% White; 60% prior chemotherapy; and 25% on dexamethasone at sample collection. Patients with oligodendrogliomas had immune profiles more similar to controls than other glioma subtypes, though with notably lower B-cells. RPA of patients with oligodendrogliomas delineated 2 survival groups based on an interaction between age and B-naïve cells. Patients with longer survival (median 24.2 years) were ≤42 years of age with higher B-naïve cells versus worse survival (median 16.9 years) who were ≤42 years of age with lower B-naïve cells or >42 years of age (P = .00032). Patients with worse survival also had lower CD4- and CD8-naïve T-cells. Similar immune profiles were observed in an independent cohort of oligodendroglioma patients prior to surgery.

Conclusions: Peripheral blood immune profiles in oligodendroglioma suggested that younger patients with lower B-naïve cells experienced shorter survival. Though our findings lack of validation cohort and use a heterogenous patient population, they suggest peripheral blood immune profiles may be prognostic for patients with glioma and warrant further investigation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信